Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 93

Cited In for PubMed (Select 15689582)

1.

Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma.

Repetto-Llamazares AH, Larsen RH, Patzke S, Fleten KG, Didierlaurent D, Pichard A, Pouget JP, Dahle J.

PLoS One. 2015 Jun 11;10(6):e0128816. doi: 10.1371/journal.pone.0128816. eCollection 2015.

2.

Introduction to radiobiology of targeted radionuclide therapy.

Pouget JP, Lozza C, Deshayes E, Boudousq V, Navarro-Teulon I.

Front Med (Lausanne). 2015 Mar 17;2:12. doi: 10.3389/fmed.2015.00012. eCollection 2015. Review.

3.

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, Bourgeois P, Vanderlinden B, van Dongen GA, Everaert H, Vaes M, Bron D.

Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1304-14. doi: 10.1007/s00259-015-3025-6. Epub 2015 Mar 20.

4.

Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

Green DJ, Shadman M, Jones JC, Frayo SL, Kenoyer AL, Hylarides MD, Hamlin DK, Wilbur DS, Balkan ER, Lin Y, Miller BW, Frost SH, Gopal AK, Orozco JJ, Gooley TA, Laird KL, Till BG, Bäck T, Sandmaier BM, Pagel JM, Press OW.

Blood. 2015 Mar 26;125(13):2111-9. doi: 10.1182/blood-2014-11-612770. Epub 2015 Jan 27.

PMID:
25628467
5.

α-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.

Teiluf K, Seidl C, Blechert B, Gaertner FC, Gilbertz KP, Fernandez V, Bassermann F, Endell J, Boxhammer R, Leclair S, Vallon M, Aichler M, Feuchtinger A, Bruchertseifer F, Morgenstern A, Essler M.

Oncotarget. 2015 Mar 10;6(7):4692-703.

6.

Radiation Dosimetry Study of [(89)Zr]rituximab Tracer for Clinical Translation of B cell NHL Imaging using Positron Emission Tomography.

Natarajan A, Gambhir SS.

Mol Imaging Biol. 2015 Aug;17(4):539-47. doi: 10.1007/s11307-014-0810-8.

PMID:
25500766
7.

Radioimmunotherapy: a specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies.

Kawashima H.

ScientificWorldJournal. 2014;2014:492061. doi: 10.1155/2014/492061. Epub 2014 Oct 14. Review.

8.

Radiopharmaceutical therapy in the era of precision medicine.

Sgouros G, Goldenberg DM.

Eur J Cancer. 2014 Sep;50(13):2360-3. doi: 10.1016/j.ejca.2014.04.025. Epub 2014 Jun 19.

PMID:
24953565
9.

Role of consolidation with yttrium-90 ibritumomab tiuxetan in patients with advanced-stage follicular lymphoma.

Sánchez Ruiz AC, de la Cruz-Merino L, Provencio Pulla M.

Ther Adv Hematol. 2014 Jun;5(3):78-90. doi: 10.1177/2040620714532282. Review.

10.

Tumor-Absorbed Dose Predicts Progression-Free Survival Following (131)I-Tositumomab Radioimmunotherapy.

Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H, Youssef E, Regan D, Wilderman SJ, Roberson PL, Kaminski MS, Avram AM.

J Nucl Med. 2014 Jul;55(7):1047-53. doi: 10.2967/jnumed.113.136044. Epub 2014 May 19.

11.

Advances in the treatment of hematologic malignancies using immunoconjugates.

Palanca-Wessels MC, Press OW.

Blood. 2014 Apr 10;123(15):2293-301. doi: 10.1182/blood-2013-10-492223. Epub 2014 Feb 27. Review.

12.

Radioimmunotherapy combined with maintenance anti-CD20 antibody may trigger long-term protective T cell immunity in follicular lymphoma patients.

Buchegger F, Larson SM, Mach JP, Chalandon Y, Dietrich PY, Cairoli A, Prior JO, Romero P, Speiser DE.

Clin Dev Immunol. 2013;2013:875343. doi: 10.1155/2013/875343. Epub 2013 Nov 26. Review.

13.

A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies.

Green DJ, Orgun NN, Jones JC, Hylarides MD, Pagel JM, Hamlin DK, Wilbur DS, Lin Y, Fisher DR, Kenoyer AL, Frayo SL, Gopal AK, Orozco JJ, Gooley TA, Wood BL, Bensinger WI, Press OW.

Cancer Res. 2014 Feb 15;74(4):1179-89. doi: 10.1158/0008-5472.CAN-13-1589. Epub 2013 Dec 26.

14.

Trial Watch: Anticancer radioimmunotherapy.

Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Sep 1;2(9):e25595. Epub 2013 Jul 3. Review.

15.

Hypothyroidism after a cancer diagnosis: etiology, diagnosis, complications, and management.

Carter Y, Sippel RS, Chen H.

Oncologist. 2014 Jan;19(1):34-43. doi: 10.1634/theoncologist.2013-0237. Epub 2013 Dec 5. Review.

16.

Targeted radionuclide therapy.

Ersahin D, Doddamane I, Cheng D.

Cancers (Basel). 2011 Oct 11;3(4):3838-55. doi: 10.3390/cancers3043838.

17.

Targeting CD19 in B-cell lymphoma: emerging role of SAR3419.

Raufi A, Ebrahim AS, Al-Katib A.

Cancer Manag Res. 2013 Aug 27;5:225-33. doi: 10.2147/CMAR.S45957. eCollection 2013. Review.

18.

Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma.

Bodet-Milin C, Ferrer L, Pallardy A, Eugène T, Rauscher A, Alain Faivre-Chauvet, Barbet J, Kraeber-Bodéré F.

Front Oncol. 2013 Jul 11;3:177. doi: 10.3389/fonc.2013.00177. eCollection 2013.

19.

Novel multifunctional antibody approved for the treatment of breast cancer.

Mavilio D, Galluzzi L, Lugli E.

Oncoimmunology. 2013 Mar 1;2(3):e24567. No abstract available.

20.

Myeloablative anti-CD20 radioimmunotherapy +/- high-dose chemotherapy followed by autologous stem cell support for relapsed/refractory B-cell lymphoma results in excellent long-term survival.

Wagner JY, Schwarz K, Schreiber S, Schmidt B, Wester HJ, Schwaiger M, Peschel C, von Schilling C, Scheidhauer K, Keller U.

Oncotarget. 2013 Jun;4(6):899-910.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk